Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

June 22, 2026 9:26 AM

Stifel analyst Paul Mattels reiterated a Buy rating and $41.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found